Assessing Dynamic Magnetic Resonance (MR) Imaging in Patients With Recurrent High Grade Glioma Receiving Chemotherapy
Status:
Terminated
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn more about imaging changes induced by a new therapeutic
agent, bevacizumab with the standard steroid, dexamethasone in patients with high grade
glioma. Magnetic resonance imaging (MRI) will be used to evaluate the difference between the
2 treatments. The usual contrast agent (gadolinium) and an iron containing contrast agent
called "ferumoxytol" may help us to evaluate the differences between bevacizumab and
dexamethasone effects on imaging of a brain tumor called high grade glioma. For this purpose,
after intravenous contrast agent injection, special MR scans (called: dynamic perfusion,
blood-brain barrier (BBB) permeability measurement) will be performed to see the
microvascular changes in the brain and tumor.
Phase:
Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
AMAG Pharmaceuticals, Inc. National Cancer Institute (NCI)